miR‐132 mediates a metabolic shift in prostate cancer cells by targeting Glut1

Prostate cancer is the second leading cause of cancer‐related deaths among men worldwide. Early diagnosis increases survival rates in patients but the survival rate has remained relatively poor over the past years. Increasing evidence shows that altered metabolism is a critical hallmark in prostate cancer. There is a strong need to explore the molecular mechanisms underlying cancer metabolism for prostate cancer therapy. Whether the aberrant...